FDA Approves Generic Equivalent to Climara Pro Hormone Patch
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The Food and Drug Administration approved the first generic version of Climara Pro on October 19, 2026. This generic patch was rated therapeutically equivalent to Bayer's Climara Pro. It is approved for women with an intact uterus to treat moderate to severe hot flashes and night sweats caused by menopause.
From medicaldaily.com
Why it matters
The approval introduces generic competition to the market for this combination hormone patch. Generic competition often leads to lower costs for patients. The patch delivers estradiol and levonorgestrel to treat menopausal symptoms and help prevent postmenopausal osteoporosis.
Generic medicine services are seeking approval for launch from the FDA.
From medicaldaily.com
Who's involved
- FDARegulatory agency that approved the generic equivalent of Climara Pro.
- Eli Lilly and CompanyThe FDA formally regulates Eli Lilly's drug development and market activities.
Keep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Unregulated products are bypassing official government approval processes.
- FDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA approval enables commercial availability for a product associated with Indianapolis.